Logo

    #21 - Tom Dayspring, M.D., FACP, FNLA – Part II of V: Lipid metrics, lipid measurements, and cholesterol regulation

    enOctober 16, 2018
    Who discovered the role of lipoproteins in lipid transport?
    What condition is caused by lipid buildup in arteries?
    What is the primary function of albumin in lipid transport?
    Which protein facilitates cholesterol absorption in the intestine?
    How does cholesterol metabolism differ between body tissues?

    Podcast Summary

    • The Role of Lipoproteins in Lipid Transportation and AtherosclerosisLipids in the human body rely on lipoproteins to transport them through the bloodstream and deliver them to specific locations. Understanding this role is crucial in understanding lipid-related diseases like atherosclerosis.

      Lipids, such as cholesterol, in the human body cannot travel on their own. They rely on lipoproteins, which are protein-wrapped structures, to transport them through the bloodstream. This discovery was made by John Hoffman in the early fifties, who realized that lipids are hydrophobic and cannot float freely in plasma. Instead, they need to be carried by lipoproteins, with albumin being a common protein carrier. Lipids inside lipoproteins can be delivered to specific locations in the body, such as the arterial wall. Atherosclerosis, a condition characterized by the buildup of lipids in the arterial wall, occurs when lipoproteins mistakenly deliver sterols to this area. Understanding the role of lipoproteins is crucial in comprehending lipid-related diseases like atherosclerosis.

    • Lipoprotein density and its impact on healthThe concentration of LDL particles plays a greater role in health than just their size or density. It is important to focus on overall LDL particle concentration rather than just their individual characteristics.

      The density of lipoproteins, which transport fats in the body, is determined by the ratio of lipid (fat) content to protein content. The larger the lipid content, the more buoyant the lipoprotein, while the smaller and denser it becomes as it loses lipids. It is incorrect to associate small size with density within each classification of lipoproteins, as there is always a range of densities within a class. The focus should not be solely on the size or density of LDLs or HDLs, but on the overall concentration of LDL particles. Having small LDLs may require a high concentration of particles, which can have a greater impact on health than just the size or density.

    • The Role of Apolipoproteins in Lipoprotein Structure and FunctionAPO B concentration can indicate the number of lipoprotein particles present, providing valuable insight into their metabolism and overall function.

      Apolipoproteins play a crucial role in determining the structure and function of lipoproteins. Lipoproteins are spherical structures with a membrane made up of phospholipids and other lipids. The apolipoprotein gives the lipoprotein its signature characteristics. Different types of lipoproteins have different apolipoproteins, such as B48, B100, and others. APO B in particular provides structural integrity to the particle and acts as the ligand for receptors that remove these particles from the plasma when they are no longer needed. Understanding the concentration of APO B can serve as a proxy for determining the number of particles present. Over time, research has identified various enzymes, receptors, and ligands involved in the metabolism of lipoproteins, leading to a better understanding of their function.

    • Understanding Lipid Metrics for Accurate Cholesterol AssessmentDifferentiating between different types of lipoproteins, such as LDL cholesterol and LDL particle number, provides a more comprehensive understanding of cholesterol levels and associated risks.

      Understanding lipid metrics is crucial for accurately assessing cholesterol levels. Total cholesterol is a measurement of the cholesterol found in all lipoproteins in the body, including chylomicrons, VLDL, intermediate density particles, LDL, and HDL. However, it does not differentiate between the different types of lipoproteins. LDL cholesterol, on the other hand, specifically measures the cholesterol carried by LDL particles, which are considered "bad" cholesterol. It is important to use proper lipid metrics and not simply refer to LDL as a laboratory metric. Differentiating between LDL cholesterol, LDL particle number, and other lipidomic factors can provide a more comprehensive understanding of cholesterol levels and associated risks.

    • Rethinking Total Cholesterol Levels as a Measure of Heart Disease RiskMeasuring specific cholesterol within APO B particles, such as LDL cholesterol, along with HDL cholesterol and triglyceride levels, provides a more accurate assessment of individual risk factors for heart disease.

      Using total cholesterol levels as a measure of heart disease risk is not accurate. The cholesterol within the APO B particles, specifically the LDL cholesterol, is what contributes to a higher risk of atherosclerosis. In the past, total cholesterol was the only clinically measurable parameter, so it was used as a crude indicator of risk. However, later studies showed that low HDL cholesterol and high triglyceride levels were even more predictive of heart attack risk. Fortunately, with the development of direct assays, we can now measure HDL cholesterol and estimate LDL cholesterol without the need for time-consuming processes like ultra centrifugation. This allows for a more accurate assessment of individual risk factors for heart disease.

    • Understanding VLDL Composition for Accurate Cholesterol AnalysisCalculating LDL cholesterol by measuring triglycerides and cholesterol ratio provides a more accurate estimate, especially when triglyceride levels are high, improving assessments of cardiovascular health.

      Understanding the composition of VLDL particles, particularly the ratio of triglycerides to cholesterol, can provide important insights into a person's cholesterol levels. By calculating the VLDL cholesterol and triglycerides divided by 5, one can determine their LDL cholesterol. This calculation is especially useful when triglyceride levels are elevated, as direct assays of LDL cholesterol may not be as accurate. However, it is important to note that the calculated LDL cholesterol is still a better estimate of LDL concentration than total cholesterol. Additionally, the introduction of non-HDL cholesterol and advancements in calculating LDL cholesterol have further improved correlations with APOB or LDL particle concentration. Overall, understanding lipoprotein metrics through techniques like NMR spectroscopy helps quantify lipoproteins more accurately and provides valuable information for assessing cardiovascular health.

    • Measuring APO B Particles for Accurate Cardiovascular Risk AssessmentMeasuring APO B particles, particularly LDL particle concentration, provides a more accurate prediction of cardiovascular risk compared to measuring cholesterol alone. Consider both APO B and LDL particle counts for an accurate assessment of risk.

      Measuring the number of APO B particles, specifically LDL particle concentration, is a more accurate predictor of cardiovascular risk than measuring cholesterol alone. APO B particles are responsible for delivering sterols into the artery walls, triggering an inflammatory process that leads to atherosclerosis. While cholesterol concentration can be measured directly, it is the number of particles that is more indicative of risk. VLDL particles also contribute to atherosclerosis, but the vast majority of APO B particles are LDL. A high APO B or LDL particle count, combined with high LDL cholesterol, signifies a significant risk. When there is a discrepancy between cholesterol levels and particle counts, the particle metric is a better indicator of risk. Therefore, both APO B and LDL particle counts should be measured to accurately assess cardiovascular risk.

    • The Importance of Knowing and Understanding Your Lipid ProfileAssessing and prioritizing LDL Particle Count (LDL P) or APO B in lipid profiles is crucial for identifying lipid-related risk and disease, despite resistance from healthcare professionals, guidelines, and payers.

      Knowing and understanding one's lipid profile, specifically the LDL Particle Count (LDL P) or APO B, is crucial for assessing lipid-related risk and screening for disease. It is disconcerting that many healthcare professionals in the United States do not prioritize these important metrics, leading patients to have to argue for their inclusion in their health assessments. Public health guidelines and third-party payers, who often resist covering the costs of additional metrics, contribute to the lag in comprehensive lipid care. The internet has both helped and confused people on this topic, with some individuals choosing to deny the significance of LDL particle concentrations. However, the overwhelming literature supports the association between elevated LDL P and atherosclerosis, making it risky to ignore this metric. While there may be exceptions, it is important to prioritize LDL P/APO B assessment until a serious study presents evidence otherwise.

    • Understanding Cholesterol: Forms, Functions, and Health Implications.Knowing the different forms and functions of cholesterol is important for maintaining vascular health, as it can lead to plaque build-up and affect various bodily functions.

      Cholesterol is a molecule with a four-ring structure and a carbon chain tail. It plays a role in vascular health and can cause plaque build-up in arterial walls. Cholesterol exists in different forms, such as free cholesterol (FC) and cholesterol ester (CE). The hydroxy group in cholesterol is soluble in water, while the carbon chain tail is not. Cholesterol ester is a storage form of cholesterol found in fat cells, and it needs to be deesterified to be utilized for various functions, such as hormone production or bile acid synthesis. Understanding the different forms and functions of cholesterol is crucial for maintaining overall health.

    • Understanding the complexity of lipids and debunking misinformation found onlineLearning about lipids and their functions in the body is essential for interpreting and debunking online misinformation about cholesterol and its impact on health.

      Lipidology, the study of lipids, is a highly complex subject that requires a deep understanding of biochemistry. Lipids, such as cholesterol, have intricate structures and properties that significantly impact their functions in the body. One key aspect discussed is the difference between cholesterol and stannals, which are saturated versions of cholesterol. Stannals cannot be absorbed by the intestines and are excreted in the feces, making them useful markers for cholesterol absorption. Understanding the complexity of lipids is crucial for interpreting and debunking misinformation found online. It emphasizes the need for education and a solid foundation in biochemistry to comprehend the intricacies of lipid metabolism and its implications for health.

    • The Risks of Phytosterol SupplementationPhytosterol supplements may not be beneficial and could be more harmful to our health than cholesterol itself. Monitoring phytosterol levels and maintaining a healthy balance of cholesterol is crucial.

      Phytosterols, which are found in plants, are not necessary for our bodies to function properly. Evolution has ensured that our intestines do not absorb phytosterols because there is a certain level at which they become toxic. Despite claims that phytosterol supplements can lower cholesterol, there is data to suggest that they may actually be more harmful to our health than cholesterol itself. This means that supplementing phytosterols may not be beneficial, especially for those who are hyper absorbers. It is important to monitor phytosterol levels in the bloodstream to avoid potentially harmful effects. Ultimately, the focus should be on maintaining a healthy balance of cholesterol rather than relying on phytosterol supplementation.

    • The Complex Process of Cholesterol Absorption and TransportationCholesterol absorption in the body involves multiple components and transporters, and understanding these complexities is crucial in maintaining healthy cholesterol levels.

      The absorption and transportation of cholesterol in our bodies is a complex process involving multiple components. Firstly, the intestine absorbs cholesterol because it is an essential ingredient for human life and evolution has ensured that every cell can synthesize cholesterol. However, it is crucial to understand that plasma cholesterol levels do not necessarily reflect cellular cholesterol metrics. The absorption of cholesterol is facilitated by the Neiman pick C1 like protein, which prefers cholesterol over other sterols due to its structure. The enterocytes, the cells in the intestine, then face the decision of whether to transport the cholesterol to the rest of the body or eliminate it. ATP binding cassette transporters play a role in either excreting cholesterol or returning it to circulation through chylomicrons or HDL. Evolution has also provided these transporters with different affinities for phytosterols and stanols, prioritizing the excretion of these compounds. An inability to efficiently excrete sterols due to loss of function mutations in ABC G5 or G8 transporters can result in hyperabsorption of cholesterol. Overall, this conversation highlights the complexities of cholesterol absorption and transportation within the body.

    • Understanding Cholesterol and its Role in the BodyThe body's cholesterol levels are influenced by various factors, with LDL cholesterol being a measure of cholesterol within lipoproteins. The reverse cholesterol transport pathway plays a significant role in eliminating cholesterol from the body.

      Cholesterol plays a complex role in the body and is influenced by various factors. LDL cholesterol, which is predominantly found in lipoproteins, is a measure of the cholesterol within these lipoproteins. When these particles invade artery walls, sterols go with them. The intestine has an enzyme called ACAT that esterifies cholesterol into cholesterol ester, a major component of the core of a column icon. However, ACAT does not favor phytosterols, which can retard their entry into the body. HDL particles can also contain phytosterols, indicating a type of dysfunctional HDL particle if measured in high amounts. The process of reverse cholesterol transport involves bringing cholesterol back to the small intestine bypassing the liver, and it can be eliminated through bowel movements. This pathway, known as trans-intestinal cholesterol efflux (TICE), is a significant contributor to cholesterol elimination, varying in individuals from 20% to 60%.

    • Managing the Review Workflow and Sharing Knowledge in the FieldThomas Dayspring's expertise in reviewing articles and sharing valuable insights helps him stay updated, while emphasizing the importance of credibility and relevant inquiries.

      Thomas Dayspring, an associate editor and reviewer, receives a significant number of articles each year for review. He estimates receiving around 15 articles as an associate editor and double that as a reviewer, totaling approximately 50 papers annually. This workload allows him to stay on top of the literature and gain valuable knowledge in the field. Peter Attia suggests creating a special group to share the most interesting lipid papers with a broader audience. Thomas agrees and suggests reaching out to him through email or following him on Twitter, where he often shares valuable insights and summaries. However, he emphasizes the need for legitimate questions and to prove credibility to avoid unnecessary or irrelevant inquiries. Overall, Thomas Dayspring's extensive exposure to research articles allows him to continually enhance his understanding of cholesterol and related subjects.

    • The Complex Pathway of Cholesterol SynthesisDisturbances in cholesterol synthesis can have serious consequences, making it important to understand the multi-stage process and the enzymes involved for maintaining a healthy cholesterol balance.

      Cholesterol synthesis is a complex multi-stage process in the body. It starts with a small molecule called acetyl coA and undergoes 20 to 30 individual steps to eventually form cholesterol. The synthetic pathway includes the production of various intermediates, with lenosterol being the first sterol that appears. There are specific enzymes involved in the pathway, such as the desaturase enzyme responsible for saturating the double bond at carbon 24 in desmosterol to convert it into cholesterol. Disturbances in this pathway can lead to conditions like Dysmosteroidosis, a genetic deficiency in the delta 24 desaturase enzyme, which can have severe consequences, especially if it occurs during pregnancy. Understanding these processes and enzymes is crucial for maintaining proper cholesterol balance in the body.

    • Understanding Cholesterol Metabolism and its ComplexityCholesterol metabolism varies in different tissues, with the brain producing its own cholesterol and the body primarily excreting it rather than using it for energy.

      Cholesterol metabolism in the body is a complex process that involves various pathways and enzymes. One important pathway is the Can Dutch Russell pathway, which plays a role in the production of cholesterol. It's worth noting that cholesterol metabolism may be tissue-specific, meaning that different tissues in the body have different mechanisms for cholesterol synthesis and utilization. Additionally, cholesterol in the brain functions independently from cholesterol in the rest of the body, as the brain produces its own cholesterol and does not rely on LDL particles for delivery. Furthermore, cholesterol can only be converted into specific substances in certain tissues, and the body primarily excretes cholesterol rather than using it for energy.

    • Cholesterol and its role in metabolismCholesterol is not metabolized like other fats and cannot be used for energy. Our bodies have evolved different pathways, like ketosis, to break down fats and preserve muscle mass. Cellular cholesterol levels are regulated for optimal function.

      Cholesterol cannot be metabolized and produce ATP like other fats. While carbon-carbon and carbon-hydrogen bonds do release energy during metabolism, the enzymatic machinery in our bodies cannot break down the bonds in cholesterol to liberate its chemical energy. This is likely a deliberate design in evolution, as metabolizing cholesterol during periods of fasting could be harmful and deplete important cell membranes and hormones. Instead, our bodies have evolved the pathway of ketosis to metabolize fats for energy, preserving muscle mass and avoiding catabolic destruction. It is also important to note that cholesterol levels in the plasma do not accurately reflect cellular cholesterol, and the synthesis, influx, and efflux of cholesterol are tightly regulated to maintain cellular function.

    • Understanding Cholesterol Homeostasis and its Importance in LipidologyCholesterol homeostasis involves the regulation of cholesterol synthesis, uptake, and circulation in the body, and understanding its movement over time is crucial in lipidology. HDL particles play a vital role in supplying cholesterol to tissues and may rely on other tissues for replenishment.

      Cholesterol homeostasis is a complex process that involves the regulation of cholesterol synthesis, uptake, and circulation in the body. While some tissues, such as the adrenal gland, can produce their own cholesterol, others rely on exogenous cholesterol sources like LDL particles. HDL particles act as a circulating reservoir of cholesterol, providing it to tissues that require it. The measurement of plasma lipids only provides information on the current state of cholesterol in the bloodstream and does not reflect what is happening within cells or endothelium. Understanding cholesterol flux and its movement over time is crucial in lipidology. In times of crisis or ongoing demand, HDLs may deplete their cholesterol stores and rely on other tissues, such as adipocytes, to replenish them.

    Recent Episodes from The Peter Attia Drive

    #317 ‒ Reforming medicine: uncovering blind spots, challenging the norm, and embracing innovation | Marty Makary, M.D., M.P.H.

    #317 ‒ Reforming medicine: uncovering blind spots, challenging the norm, and embracing innovation | Marty Makary, M.D., M.P.H.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Marty Makary, a Johns Hopkins surgeon and New York Times bestselling author, returns to The Drive to discuss his latest book, Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health. In this episode, Marty explores how a new generation of doctors is challenging long-held medical practices by asking critical new questions. He discusses the major problems of groupthink and cognitive dissonance in the medical community and delves into several of the "blind spots" raised in the book, including treatments for appendicitis, the peanut allergy epidemic, misunderstandings about HRT and breast cancer, antibiotic use, and the evolution of childbirth. He explains the urgent need for reform in medical education and the major barriers standing in the way of innovative medical research. Throughout the conversation, Marty offers insightful reflections on where medicine has succeeded and where there’s still room to challenge historic practices and embrace new approaches.

    We discuss:

    • The issue of groupthink and cognitive dissonance in science and medicine [2:30];
    • How a non-operative treatment for appendicitis sheds light on cognitive dissonance [7:00];
    • How cognitive dissonance and effort justification shape beliefs and actions [13:15];
    • How misguided peanut allergy recommendations created an epidemic [17:45];
    • The enduring impact of misinformation and fear-based messaging around hormone replacement therapy allegedly causing breast cancer [25:15];
    • The dangers of extreme skepticism and blind faith in science, and the importance of understanding uncertainty and probability [28:00];
    • The overuse of antibiotics and the rise of antibiotic resistant infections and poor gut health [33:45];
    • The potential correlations between early antibiotic use and chronic diseases [40:45];
    • The historical and evolving trends in childbirth and C-section rates [50:15];
    • Rethinking ovarian cancer: recent data challenging decades of medical practice and leading to new preventive measures [1:05:30];
    • Navigating uncertainty as a physician [1:19:30];
    • The urgent need for reform in medical education [1:21:45];
    • The major barriers to innovative medical research [1:27:30];
    • The dogmatic culture of academic medicine: why humility and challenging established norms are key for progress [1:38:15];
    • The major successes and ongoing challenges of modern medicine [1:51:00]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enSeptember 16, 2024

    #316 - AMA #63: A guide for hair loss: causes, treatments, transplants, and sex-specific considerations

    #316 - AMA #63: A guide for hair loss: causes, treatments, transplants, and sex-specific considerations

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    In this “Ask Me Anything” (AMA) episode, Peter dives deep into the topic of hair loss, exploring its relationship with aging and its impact on quality of life. The conversation focuses on androgenic alopecia, the most common form of hair loss in both men and women, and covers the differences in patterns and causes between the sexes. Peter delves into the right timing for treatment, breaking down various options such as minoxidil and finasteride, low-level laser therapy, platelet-rich plasma injections, and more. Additionally, Peter outlines the pros and cons of the two primary hair transplantation methods and concludes with practical advice on selecting the right specialist or treatment team for those facing hair loss.

    If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #63 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

    We discuss:

    • The impact of hair loss on emotional health [2:15];
    • The prevalence, patterns, and causes of hair loss in men and women [5:15];
    • The genetic and hormonal causes of hair loss, and the role of dihydrotestosterone (DHT) in androgenic alopecia [8:45];
    • The visual differences in hair loss patterns between men and women, and the importance of consulting a specialist to rule out non-genetic causes of hair loss [13:30];
    • How genetic predisposition influences the risk of androgenic alopecia, and how early detection through diagnostic tools and blood tests can help manage risk more effectively [16:45];
    • Ideal timing for starting treatment: why early treatment is crucial for effectively managing hair loss [19:30];
    • The various FDA-approved treatments for androgenic alopecia, their mechanisms, and additional off-label treatments commonly used to manage hair loss [24:30];
    • Topical minoxidil—the most commonly recommended starting treatment for hair loss [30:15];
    • Oral vs. topical minoxidil: efficacy, ease of use, and potential side effects that must be considered [33:45];
    • Finasteride for treating hair loss: efficacy, potential side effects on libido, and the need for careful PSA monitoring in men to avoid missing early signs of prostate cancer [37:15];
    • Other effective hair loss treatments for women: boosting hair density with spironolactone gel and ketoconazole shampoo as part of a comprehensive strategy [41:30];
    • Low-level laser therapy: effectiveness, costs, practicality, and a comparison of in-office treatments with at-home devices [49:00];
    • Platelet-rich plasma (PRP) as a treatment for hair loss: potential effectiveness, varying protocols, and significant costs [53:45];
    • Hair transplant for advanced hair loss: criteria and considerations [58:00];
    • Types of hair transplants: follicular unit transplantation (FUT) vs. follicular unit extraction (FUE) [1:02:00];
    • The financial cost of hair transplant surgery, and what to consider when seeking affordable options [1:06:15];
    • The potential risks and downsides of the various hair transplant procedures [1:09:30];
    • Post-procedure care for hair transplants and whether the procedure must be repeated periodically [1:16:30];
    • Combining different hair loss treatments: benefits, risks, and considerations [1:18:30];
    • Emerging hair loss treatments with limited data [1:21:00];
    • Key considerations for selecting the right treatment plan for hair loss [1:22:00];
    • A summary of the different considerations for men and women facing hair loss [1:24:30];
    • Practical advice on selecting the right specialist or treatment team [1:26:15]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enSeptember 09, 2024

    Improve your decision-making, frameworks for learning, backcasting, and more | Annie Duke (#60 rebroadcast)

    Improve your decision-making, frameworks for learning, backcasting, and more | Annie Duke (#60 rebroadcast)

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    In this episode, former World Series of Poker champion and author Annie Duke explains how poker is a pertinent model system for decision-making in the real world, a system which blends imperfect information with some unknown percentage of both luck and skill. Annie breaks down the decision-making matrix, revealing how we often focus too narrowly on just one of the four quadrants, missing out on valuable learning opportunities in the remaining 75% of situations. She delves into how our tendency to evaluate only negative outcomes leads to a culture of risk aversion. This mindset, she argues, stifles the kind of bold decision-making necessary for progress and innovation across various fields, from poker and sports to business and medicine. Annie also introduces a robust framework for learning and the levels of thought required to excel in any domain. Finally, she discusses a strategy called “backcasting”, a concept that resonated deeply with Peter in terms of how he thinks about extending healthspan.

    We discuss:

    • Annie’s background, favorite sports teams, and Peter’s affinity for Bill Belichick [1:30];
    • Chess vs. poker: Which is a better metaphor for decision-making in life (and medicine)? [6:45];
    • Thinking probabilistically: Why we aren’t wired that way, and how you can improve it for better decision-making [12:30];
    • Variable reinforcement: The psychological draw of poker that keeps people playing [19:15];
    • The role of luck and skill in poker (and other sports), and the difference between looking at the short run vs. long run [32:15];
    • A brief explanation of Texas hold ‘em [41:00];
    • The added complexity of reading the behavior of others players in poker [47:30];
    • Why Annie likes to “quit fast,” and why poker is still popular despite the power of loss aversion [52:45];
    • Limit vs. no-limit poker, and how the game has changed with growing popularity [55:15];
    • The advent of analytics to poker, and why Annie would get crushed against today’s professionals [1:04:45];
    • The decision matrix, and the “resulting” heuristic: The simplifier we use to judge the quality of decisions —The Pete Carroll Superbowl play call example [1:10:30];
    • The personal and societal consequences of avoiding bad outcomes [1:21:45];
    • Poker as a model system for life [1:31:30];
    • How many leaders are making (and encouraging) status-quo decisions, and how Bill Belichick’s decision-making changed after winning two Super Bowls [1:35:15];
    • What did we learn about decision-making from the Y2K nothingburger? And how about the D-Day invasion? [1:39:30];
    • The first step to becoming a good decision maker [1:43:00];
    • The difference between elite poker players and the ones who make much slower progress [1:49:45];
    • Framework for learning a skill, the four levels of thought, and why we hate digging into our victories to see what happened [1:52:15];
    • The capacity for self-deception, and when it is MOST important to apply four-level thinking [2:00:30];
    • Soft landings: The challenge of high-level thinking where there is subtle feedback and wider skill gaps [2:11:00];
    • The benefits of “backcasting” (and doing pre-mortems) [2:13:30];
    • Parting advice from Annie for those feeling overwhelmed (and two book recommendations) [2:21:30]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enSeptember 02, 2024

    #315 ‒ Life after near-death: a new perspective on living, dying, and the afterlife | Sebastian Junger

    #315 ‒ Life after near-death: a new perspective on living, dying, and the afterlife | Sebastian Junger

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Sebastian Junger is an award-winning journalist, bestselling author, and previous guest on The Drive. In this episode, Sebastian returns to discuss his latest book, In My Time of Dying: How I Came Face to Face with the Idea of an Afterlife. This episode delves into Sebastian's profound near-death experience and how it became the catalyst for his exploration of mortality, the afterlife, and the mysteries of the universe. They discuss the secular meaning of what it means to be sacred, the intersection of physics and philosophy, and how our beliefs shape our approach to life and death. He also shares how this experience has profoundly changed him, giving him a renewed perspective on life—one filled with awe, gratitude, deeper emotional awareness, and a more engaged approach to living.

    We discuss:

    • How Sebastian’s near-death experience shaped his thinking about mortality and gave him a reverence for life [3:00];
    • The aneurysm that led to Sebastian’s near-death experience [6:30];
    • Emergency room response, his subsequent reflections on the event, and the critical decisions made by the medical team [16:30];
    • Sebastian’s reaction to first learning he nearly died, and the extraordinary skill of the medical team that save his life [26:00];
    • Sebastian’s near-death experience [37:00];
    • The psychological impact of surviving against overwhelming odds [48:00];
    • Ignored warning signs: abdominal pain and a foreshadowing dream before the aneurysm rupture [54:30];
    • Sebastian's recovery, his exploration of near-death experiences, and the psychological turmoil he faced as he questioned the reality of his survival [58:15];
    • A transformative encounter with a nurse who encouraged Sebastian to view his near-death experience as sacred [1:03:30];
    • How Sebastian has changed: a journey toward emotional awareness and fully engaging with life [1:08:45];
    • The possibility of an afterlife, and how quantum mechanics challenges our understanding of existence [1:15:15];
    • Quantum paradoxes leading to philosophical questions about the nature of reality, existence after death, and whether complete knowledge could be destructive [1:26:00];
    • The sweet spot of uncertainty: exploring belief in God, post-death existence, and meaning in life [1:37:00];
    • The transformative power of experiencing life with awe and gratitude [1:53:00]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enAugust 26, 2024

    #314 ‒ Rethinking nutrition science: the evolving landscape of obesity treatment, GLP-1 agonists, protein, and the need for higher research standards | David Allison, Ph.D.

    #314 ‒ Rethinking nutrition science: the evolving landscape of obesity treatment, GLP-1 agonists, protein, and the need for higher research standards | David Allison, Ph.D.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    David Allison, a leading expert in obesity and nutrition, quantitative genetics, clinical trials, and research methodology, returns to The Drive to explore the evolving landscape of nutrition science and obesity treatment. In this episode, David begins by discussing the intricate relationship between nutrition, obesity, and body composition, emphasizing the multifaceted impacts of food beyond mere calorie intake. David provides a critical analysis of the complexities in nutrition research and their practical implications for tackling obesity. He critiques historical public health policies, addresses the trust issues plaguing nutrition science, and underscores the need for a paradigm shift to more effectively combat obesity. The conversation also delves into the rise of GLP-1 receptor agonists like Ozempic and Mounjaro, exploring their ethical and practical considerations in obesity treatment. The episode concludes with an in-depth look at protein intake recommendations and highlights the significant research gaps that remain in the field.

    We discuss:

    • The complex relationship between nutrition, body weight, and body composition [2:30];
    • The slow progress in addressing obesity and public health despite substantial effort and investment [7:30];
    • The very limited success of public health initiatives in curbing obesity [17:15];
    • The evolving landscape of obesity research: public health initiatives and the impact of pharmacological success [26:30];
    • Rethinking obesity solutions: the need for a paradigm shift [32:45];
    • Understanding environmental triggers and embracing a balanced approach to addressing obesity that includes both pharmacological treatments and realistic lifestyle changes [41:45];
    • The need for higher standards in obesity research [51:45];
    • The rapid success of GLP-1 receptor agonists for weight loss: a discussion on the societal impact and controversy of their growing usage [1:02:15];
    • The ethical and practical considerations of obesity drugs: risks, benefits, and motivations for usage [1:11:30];
    • The use of GLP-1 agonists by athletes as performance enhancers [1:23:45];
    • Unanswered questions about protein intake and health [1:30:45];
    • Future research needed to understand basic questions around protein intake [1:45:00];
    • David’s weekly newsletter: “Obesity and Energetics Offerings” [1:50:45]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enAugust 19, 2024

    #313 - AMA #62: Protein’s impact on appetite and weight management, and uric acid's link to disease and how to manage levels

    #313 - AMA #62: Protein’s impact on appetite and weight management, and uric acid's link to disease and how to manage levels

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    In this “Ask Me Anything” (AMA) episode, Peter dives into two important health topics: uric acid and protein, examining them from unique perspectives. For uric acid, he explores its metabolic role and connection to various diseases, focusing on the potential causal link with cardiovascular disease. He also discusses factors influencing uric acid levels, such as diet, genetics, and lifestyle, providing practical tips for effective management. Shifting to protein, Peter delves into its role in appetite and weight management, the consequences of insufficient protein, and the “protein leverage hypothesis” linking protein deficiency to obesity. He covers optimal protein intake and its impact on energy expenditure, and he compares the satiety effects of solid versus liquid protein. Finally, Peter shares his strategy for incorporating protein into a comprehensive weight management plan.

    If you’re not a subscriber and are listening on a podcast player, you’ll only be able to hear a preview of the AMA. If you’re a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #62 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here.

    We discuss:

    • Overview of episode topics (and an important discussion on fanny packs) [2:00];
    • Understanding uric acid: its role in metabolic processes, its association with gout and kidney stones, its impact on blood pressure, and more [6:00];
    • Non-modifiable factors that influence uric acid levels [11:00];
    • Modifiable factors that influence uric acid levels [14:15];
    • Association between high uric acid levels and cardiovascular disease [20:00];
    • Evidence suggesting a causal link between high uric acid levels and cardiovascular disease [24:00];
    • Inconclusive evidence about the cardiovascular benefits of lowering uric acid pharmacologically [28:15];
    • Exploring the potential risks of low uric acid levels in neurodegenerative diseases [37:00];
    • Managing uric acid levels: dietary interventions and pharmacological approaches [42:00];
    • The impact of protein on appetite and weight management [44:00];
    • The consequences of insufficient protein on eating behaviors and satiety [52:15];
    • The relationship between protein deficiency and obesity: exploring the “protein leverage hypothesis” [57:15];
    • The impact of protein intake on energy expenditure [1:02:15];
    • Determining optimal protein intake to avoid deficiency and support health [1:05:45];
    • The role of different amino acids and protein sources in promoting satiety [1:08:15];
    • Comparing the satiety effects of solid vs. liquid protein sources [1:10:30];
    • Peter’s framework for incorporating protein intake into a strategy for controlling body weight [1:12:00]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enAugust 12, 2024

    #312 - A masterclass in lactate: Its critical role as metabolic fuel, implications for diseases, and therapeutic potential from cancer to brain health and beyond | George A. Brooks, Ph.D.

    #312 - A masterclass in lactate: Its critical role as metabolic fuel, implications for diseases, and therapeutic potential from cancer to brain health and beyond | George A. Brooks, Ph.D.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    George A. Brooks is a renowned professor of integrative biology at UC Berkeley. Known for his groundbreaking "lactate shuttle" theory proposed in the 1980s, George revolutionized our understanding of lactate as a crucial fuel source rather than just a byproduct of exercise. In this episode, George clarifies common misconceptions between lactate and lactic acid, delves into historical perspectives, and explains how lactate serves as a fuel for the brain and muscles. He explores the metabolic differences in exceptional athletes and how training impacts lactate flux and utilization. Furthermore, George reveals the significance of lactate in type 2 diabetes, cancer, and brain injuries, highlighting its therapeutic potential. This in-depth conversation discusses everything from the fundamentals of metabolism to the latest research on lactate's role in gene expression and therapeutic applications.

    We discuss:

    • Our historical understanding of lactate and muscle metabolism: early misconceptions and key discoveries [3:30];
    • Fundamentals of metabolism: how glucose is metabolized to produce ATP and fuel our bodies [16:15];
    • The critical role of lactate in energy production within muscles [24:00];
    • Lactate as a preferred fuel during high-energy demands: impact on fat oxidation, implications for type 2 diabetes, and more [30:45];
    • How the infusion of lactate could aid recovery from traumatic brain injuries (TBI) [43:00];
    • The effects of exercise-induced lactate [49:30];
    • Metabolic differences between highly-trained athletes and insulin-resistant individuals [52:00];
    • How training enhances lactate utilization and facilitates lactate shuttling between fast-twitch and slow-twitch muscle fibers [58:45];
    • The growing recognition of lactate and monocarboxylate transporters (MCT) [1:06:00];
    • The intricate pathways of lactate metabolism: isotope tracer studies, how exceptional athletes are able to utilize more lactate, and more [1:09:00];
    • The role of lactate in cancer [1:23:15];
    • The role of lactate in the pathophysiology of various diseases, and how exercise could mitigate lactate's carcinogenic effects and support brain health [1:29:45];
    • George’s current research interests involving lactate [1:37:00];
    • Questions that remain about lactate: role in gene expression, therapeutic potential, difference between endogenous and exogenous lactate, and more [1:50:45]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enAugust 05, 2024

    #311 ‒ Longevity 101: a foundational guide to Peter's frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more

    #311 ‒ Longevity 101: a foundational guide to Peter's frameworks for longevity, and understanding CVD, cancer, neurodegenerative disease, nutrition, exercise, sleep, and more

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    In this special episode, Peter provides a comprehensive introduction to longevity, perfect for newcomers or those looking to refresh their knowledge. He lays out the foundational concepts of lifespan, healthspan, and the marginal decade. Additionally, Peter discusses the four main causes of death and their prevention, as well as detailing the five key strategies in his longevity toolkit to improve lifespan and healthspan. Detailed show notes provide links for deeper exploration of these topics, making it an ideal starting point for anyone interested in understanding and improving their longevity.

    We discuss:

    • Key points about starting exercise as an older adult [2:45];
    • Overview of episode topics and structure [1:45];
    • How Peter defines longevity [3:45];
    • Why healthspan is a crucial component of longevity [11:15];
    • The evolution of medicine from medicine 1.0 to 2.0, and the emergence of medicine 3.0 [15:30];
    • Overview of atherosclerotic diseases: the 3 pathways of ASCVD, preventative measures, and the impact of metabolic health [26:00];
    • Cancer: genetic and environmental factors, treatment options, and the importance of early and aggressive screening [33:15];
    • Neurodegenerative diseases: causes, prevention, and the role of genetics and metabolic health [39:30];
    • The spectrum of metabolic diseases [43:15];
    • Why it’s never too late to start thinking about longevity [44:15];
    • The 5 components of the longevity toolkit [46:30];
    • Peter’s framework for exercise—The Centenarian Decathlon [47:45];
    • Peter’s nutritional framework: energy balance, protein intake, and more [58:45];
    • Sleep: the vital role of sleep in longevity, and how to improve sleep habits [1:08:30];
    • Drugs and supplements: Peter’s framework for thinking about drugs and supplements as tools for enhancing longevity [1:13:30];
    • Why emotional health is a key component of longevity [1:17:00];
    • Advice for newcomers on where to start on their longevity journey [1:19:30]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJuly 29, 2024

    #310 - The relationship between testosterone and prostate cancer, testosterone replacement therapy, and tools for predicting cancer aggressiveness and guiding therapy | Ted Schaeffer, M.D., Ph.D.

    #310 - The relationship between testosterone and prostate cancer, testosterone replacement therapy, and tools for predicting cancer aggressiveness and guiding therapy | Ted Schaeffer, M.D., Ph.D.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Ted Schaeffer is an internationally recognized urologist specializing in prostate cancer and a returning guest on The Drive. In this episode, Ted provides insights into the role testosterone plays, or doesn't play, in the initiation and progression of prostate cancer. He unpacks the findings and limitations of the recent TRAVERSE trial, exploring the complex relationship between testosterone and prostate cancer. Ted delves into the molecular nature of prostate cancer, explaining the androgen receptor saturation theory and the potential impact of testosterone on cancer growth. He also discusses the use of the Decipher test to predict cancer aggressiveness and guide targeted treatment. Furthermore, Ted shares how he counsels patients regarding testosterone replacement therapy (TRT), including its safe administration in patients with low-grade prostate cancer. Additionally, he highlights advancements in prostate cancer therapies and biomarkers that help develop precise treatment strategies while minimizing the need for broad androgen deprivation therapy.

    We discuss:

    • Background on the TRAVERSE trial: insights into exogenous testosterone and prostate cancer risk [3:00];
    • The androgen receptor saturation theory: how different organs respond to varying levels of testosterone [10:30];
    • The relationship between testosterone levels and prostate cancer aggressiveness: how aggressive prostate tumors have lower androgen receptor activity and rely on different growth mechanisms [16:15];
    • Using the Decipher score to assess prostate cancer aggressiveness and guide personalized treatment strategies [23:45];
    • Considerations for testosterone replacement therapy: how Ted counsels patients, how TRT can be safely administered in patients with low-grade prostate cancer, and more [31:15];
    • Advancements in prostate cancer therapies and PSA as a biomarker for precise treatment decisions, minimizing the need for broad androgen deprivation therapy [38:30]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJuly 22, 2024

    #309 ‒ AI in medicine: its potential to revolutionize disease prediction, diagnosis, and outcomes, causes for concern in medicine and beyond, and more | Isaac Kohane, M.D., Ph.D.

    #309 ‒ AI in medicine: its potential to revolutionize disease prediction, diagnosis, and outcomes, causes for concern in medicine and beyond, and more | Isaac Kohane, M.D., Ph.D.

    View the Show Notes Page for This Episode

    Become a Member to Receive Exclusive Content

    Sign Up to Receive Peter’s Weekly Newsletter

    Isaac "Zak" Kohane, a pioneering physician-scientist and chair of the Department of Biomedical Informatics at Harvard Medical School, has authored numerous papers and influential books on artificial intelligence (AI), including The AI Revolution in Medicine: GPT-4 and Beyond. In this episode, Zak explores the evolution of AI, from its early iterations to the current third generation, illuminating how it is transforming medicine today and unlocking astonishing possibilities for the future. He shares insights from his unconventional journey and early interactions with GPT-4, highlighting significant AI advancements in image-based medical specialties, early disease diagnosis, and the potential for autonomous robotic surgery. He also delves into the ethical concerns and regulatory challenges of AI, its potential to augment clinicians, and the broader implications of AI achieving human-like creativity and expertise.

    We discuss:

    • Zak’s unconventional journey to becoming a pioneering physician-scientist, and his early interactions with GPT-4 [2:15];
    • The evolution of AI from the earliest versions to today’s neural networks, and the shifting definitions of intelligence over time [8:00];
    • How vast data sets, advanced neural networks, and powerful GPU technology have driven AI from its early limitations to achieving remarkable successes in medicine and other fields [19:00];
    • An AI breakthrough in medicine: the ability to accurately recognize retinopathy [29:00];
    • Third generation AI: how improvements in natural language processing significantly advanced AI capabilities [32:00];
    • AI concerns and regulation: misuse by individuals, military applications, displacement of jobs, and potential existential concerns [37:30];
    • How AI is enhancing image-based medical specialties like radiology [49:15];
    • The use of AI by patients and doctors [55:45];
    • The potential for AI to augment clinicians and address physician shortages [1:02:45];
    • The potential for AI to revolutionize early diagnosis and prediction of diseases: Alzheimer’s disease, CVD, autism, and more [1:08:00];
    • The future of AI in healthcare: integration of patient data, improved diagnostics, and the challenges of data accessibility and regulatory compliance [1:17:00];
    • The future of autonomous robotic surgery [1:25:00];
    • AI and the future of mental health care [1:31:30];
    • How AI may transform and disrupt the medical industry: new business models and potential resistance from established medical institutions [1:34:45];
    • Potential positive and negative impacts of AI outside of medicine over the next decade [1:38:30];
    • The implications of AI achieving a level of creativity and expertise comparable to exceptional human talents [1:42:00];
    • Digital immortality and legacy: the potential to emulate an individual's personality and responses and the ethical questions surrounding it [1:45:45];
    • Parting thoughts [1:50:15]; and
    • More.

    Connect With Peter on TwitterInstagramFacebook and YouTube

    The Peter Attia Drive
    enJuly 15, 2024

    Related Episodes

    #22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

    #22 - Tom Dayspring, M.D., FACP, FNLA – Part III of V: HDL, reverse cholesterol transport, CETP inhibitors, and apolipoproteins

    In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part III, Peter and Tom dig into HDL, why "reverse cholesterol transport" is a lot more nuanced than what most of us are taught, lipid transport, apolipoproteins, and more. In addition, this episode highlights the complexity of HDL and a discussion about the CETP inhibitor trials.

    We discuss:

    • Reverse cholesterol transport [1:40];
    • Lipid transportation, apolipoproteins, VLDL, IDL, and LDL particles [11:00];
    • Remnant lipoproteins and apoC-III [16:45];
    • Particles having sex: lipid exchange [28:00];
    • Cholesteryl Ester Transfer Protein (CETP) and CETP inhibitors [40:45];
    • 2006 CETP inhibitor trial: torcetrapib (Pfizer) [54:45];
    • 2012 CETP inhibitor trial: dalcetrapib (Hoffmann–La Roche) [56:15];
    • 2017 CETP inhibitor trials: evacetrapib (Eli Lilly) and anacetrapib (Merck) [58:00]; and
    • More.

    Learn more at www.PeterAttiaMD.com

    Connect with Peter on Facebook | Twitter | Instagram.

    Pe124 Cannabis 301: Beyond Cannabinoids & Terpenes

    Pe124 Cannabis 301: Beyond Cannabinoids & Terpenes

    Cannabis is one of the most complex plants on Earth, which is why it’s known to help with so many different use cases. As we discover more about the science of cannabis it becomes difficult to predict which products will work for different use cases. Our guest is Educator Emma Chasen and we discuss how the many compounds in cannabis could be useful for different effects and ailments.

    Link to Email List sign up “Join our Community” and get insights we don’t share anywhere else.

    #23 - Tom Dayspring, M.D., FACP, FNLA – Part IV of V: Statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain

    #23 - Tom Dayspring, M.D., FACP, FNLA  – Part IV of V: Statins, ezetimibe, PCSK9 inhibitors, niacin, cholesterol and the brain

    In this five-part series, Thomas Dayspring, M.D., FACP, FNLA, a world-renowned expert in lipidology, and one of Peter's most important clinical mentors, shares his wealth of knowledge on the subject of lipids. In Part IV, Peter and Tom review the history and current use of drugs to prevent cardiovascular disease. They also discuss why some drugs appear to be more effective than others, an in-depth conversation about niacin, cholesterol and brain health, and the futility of using CKs (creatinine kinase) and liver function tests to identify adverse effects in statins, to name a few topics in this episode.

    We discuss:

    • Bile acid sequestrants and statins [2:00];
    • Ezetimibe (Zetia) [15:00];
    • PCSK9 inhibitors [27:30];
    • Fibrates [41:00];
    • Fish oil, DHA, and EPA [1:01:00];
    • Niacin [1:05:15];
    • PCSK9 inhibitors [1:23:45];
    • Cholesterol, statins, and the brain [1:30:00];
    • Elevated creatine kinase (CK) and liver function tests (LFTs) on statins [1:50:30]; and
    • More.

    Learn more at www.PeterAttiaMD.com

    Connect with Peter on Facebook | Twitter | Instagram.

    Episode 121: Good Versus Bad - A Medical Discussion

    Episode 121: Good Versus Bad - A Medical Discussion

    This week, Jonathan is joined by William Barrett, a talented surgeon. They discuss Barrett’s career in the USA and in other countries where he volunteered, and why he did not continue his career in research. They also talk about the vilification of fats and how social media can be used as a way of alerting healthcare professionals when new research is available, as well as Barrett’s work with Mercy Ships, an international non-profit organisation, where he performed surgeries while on a boat.

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io